



MicroPort Scientific Corporation

2021 Interim Results

31 August 2021



115

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, “anticipate”, “project”, “estimate”, “predict”, “is confident”, “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

Contents

- 1 Interim Result Highlights
- 2 Financial Review
- 3 Business Review
- 4 Outlook
- 5 Appendix – Financial Statements



Interim Result Highlights

Neurovascular
\$ 25.4mn **↑114.5%YOY**

Heart Valve
\$ 13.4mn **↑121.8%YOY**

CRM
\$ 108.3mn **↑20.0%YOY**


Cardiovascular
\$ 66.8mn **-29.9%YOY**

Endovascular
\$ 55.8mn **↑68.6%YOY**

Orthopedics
\$ 110.1mn **↑22.9%YOY**

Surgical Devices
\$ 2.3mn **-1.6%YOY**

Surgical Robot
IPO application accepted



Revenue

\$ 384.6mn
↑17.7%YOY



- ◆ **Cardiovascular:** DES sales volume **+111.9%**
Balloon sales volume **+92.3%**
- ◆ **Orthopedics:** China +37.5% (made-in-China joints **+116.9%**); Overseas +20.9%
- ◆ **CRM:** China **+95.0%**; Overseas +17.3% (US **+87.3%**, Japan **45.8%**, EMEA **+16.1%**)
- ◆ **Endovascular:** **+68.6%**
- ◆ **Neurovascular:** **+114.5%**
- ◆ **Heart Valve:** **+121.8%**

R&D Expenses

\$ 117.1mn
↑60.8%YOY
~30% of Sales



- 8** NMPA Approvals
- 1** NMPA Green Path - **No.1** in industry
- 14** CE & **2** FDA Approvals
- ◆ **Firehawk®:** proceeded **TARGET IV NA (US)** & launched **TARGET FIRST** clinical trials **(EU)**
- ◆ **Toumai® & Honghu:** NMPA registration stage
- ◆ **Invicta™ ICD lead:** completed **1st** patient enrollment in clinical trial

Strong Balance Sheet



- ◆ External fund raising: **~\$1.21bn***
- ◆ Period end cash balance: **\$1.7bn**

Note: Revenue growth rate adjusted to exclude foreign exchange impact
* Including CRM \$150mn equity fund raising announced in Jul 21



External Financing

Raised **~\$1.21bn** in total from external equity financing



Strategic Investment

Developed strategic collaboration relationships with leading companies around the globe



Domestic

NMPA Approvals* **8**

1 product entered Green Path
21 products accumulatively - **No.1** in industry



Cardio-vascular

- ◆ Firesorb®'s **FUTURE-II** trial 1-year results proved comparable angiographic and clinical efficacy to world's leading coronary drug-eluting stents



Ortho-pedics

- ◆ Profemur® Femoral Stem & VenusOne Bio-acetabular system in **registration stage**



CRM

- ◆ Platinum™ ICDs, Platinum™ CRT-Ds & BeFlex™ MRI lead **submitted for approval**
- ◆ ENO™/TEO™/OTO™ pacemakers & Vega™ lead finished **CAPRI 1st** clinical enrollment



Endo-vascular

- ◆ Talos® Thoracic Stent Graft & Fontus® Surgical Stent Graft **submitted for approval**
- ◆ TIPS Stent Graft completed animal study



Neuro-vascular

- ◆ **NUMEN® Silk** 3-D Coil Embolization System, Intracranial Distal Access Catheter & **Diveer™** Intracranial Balloon Catheter **submitted for approval**
- ◆ Tubridge® completed patient enrollment of **IMPACT** trail (Aug 21)



Heart Valve

- ◆ **Alwide® Plus** **obtained NMPA** (Aug 21)
- ◆ VitaFlow®'s 4-year follow-up study proved safety and efficacy for long-term use



Surgical Robot

- ◆ **DFVision®** 3D Electronic Laparoscope **obtained NMPA**
- ◆ **Toumai®** Laparoscopic Surgical Robot **submitted for approval**
- ◆ **Honghu** Orthopedic Surgical Robot **submitted for approval** (Jul 21)



Surgical Business

- ◆ **VitaSprings™** Membrane Oxygenator completed clinical trial



Electro-physiology¹

- ◆ Disposable Intracardiac Mapping Catheter **obtained NMPA**
- ◆ **IceMagic®** Cryoablation System **entered Green Path** & finished clinical trail enrollment
- ◆ Contact Force Sensing Cardiac RF Ablation Catheter finished clinical trail enrollment



ART¹

- ◆ **Orkid®** Intrauterine Insemination Catheter **obtained NMPA**



Sports Medicine

- ◆ Performed the **first implantation** of Archimedes® - **World's 1st long-term implantable rotator cuff spacer system**

Overseas

CE Approvals **14**

FDA Approvals **2**



Cardio-vascular

- ◆ DES: **10** approvals in 9 countries/regions
- ◆ Balloon: **7** approvals in 4 countries/regions
- ◆ **Firehawk®** proceeded TARGET IV NA trial (**US**) & launched TARGET FIRST trial (**EU**)



Ortho-pedics

- ◆ **CE**: Profemur® Cemented Femoral Stem, Procotyl® P Cup & Hip Head Tensioner
- ◆ **CE & FDA**: Evolution® Kinematic Alignment & Anterior PATH® instruments



CRM

- ◆ **CE**: **Alizea™/Borea™** pacemakers & **SmartView Connect™** home monitor; Ulys™ /Edis™ /Gali™ ICD
- ◆ Invicta™ ICD lead completed **1st patient enrollment**



Endo-vascular

- ◆ Castor® completed 1st implantation in **Spain, Argentina & Italy**



Neuro-vascular

- ◆ **NUMEN® & NUMEN FR® CE certified**



Heart Valve

- ◆ **VitaFlow®** completed 1st overseas commercial implantation in **Argentina** (Aug 21)



Surgical Business

- ◆ Suction tube **CE certified**
- ◆ Venous cannula & arterial micro-embolic filter **approved** in **Colombia**



Electro-physiology¹

- ◆ Columbus® completed 1st Procedure in **Brazil**
- ◆ **5** products approved in **Australia**



ART¹

- ◆ Daylily® Embryo Transfer Catheter & Lotus™ Ovum Aspiration Needle **approved** in **Thailand**



IVD

- ◆ Self-developed **2019-nCoV PCR Test Kit CE certified** (Aug 21)



Nonvascular Intervention

- Provide solutions to **urinary, gynecological, digestive & respiratory** diseases
- **2** products newly **approved by NMPA**; **2** in registration stage
- **Ureteroscope** upon launch with multiple single-use scope product lines
- Kidney stone management product covered **70+** hospitals



Sports Medicine

- Complete sports medicine portfolio with innovative & robust shoulder solutions
- **The world's 1st long-term implantable rotator cuff spacer system**, with proved clinical evidence
- **4** products upon NMPA approval



Assisted Reproductive Technology

- **Orkid[®]** Intrauterine Insemination Catheter newly **approved by NMPA**
- Embryo Transfer Catheter & Ovum Aspiration Needle newly **approved** in Thailand



Rehabilitation

- Focus on **muscle & bone** rehabilitation, **cardiopulmonary** rehabilitation and **neurological** rehabilitation
- **6 approved** products with multiple product lines
- Obtained **~100** patents
- Mobile assistive product newly **approved by NMPA**



Endocrinology

- **Core platform:** micro-infusion technology
- **La Fenice[®] Insulin Pump** sales increased substantially, owing to online channels development
- **Chemotherapy pump** in registration stage



IVD

- **High-tech diagnostic** solution provider
- Self-developed 2019-nCoV PCR Test Kit **approved by CE**



Medical Imaging

- Provide precise interventional imaging solution
- **DSA** in **NMPA** registration stage




Aesthetic

- Provide solutions incl. **facial rejuvenation, body contouring & hair Loss treatment**



ENT, Ophthalmology & Dental

- **Ophthalmological treatment:** cataract, ametropia & glaucoma
- **Innovative solutions:** sinus, inner ear drug delivery system & artificial hearing repair
- Orthodontics & dental implant



Sterilization


- **Obtained certificates:** ISO13485 & ISO11135, Japan Registration Certificate
- Rapid revenue growth driven by **increased customer base**

Contents

- 1 Interim Result Highlights
- 2 Financial Review
- 3 Business Review
- 4 Outlook
- 5 Appendix – Financial Statements

Revenue

USD: million




Gross Profit Margin



Operating Expenses

USD: million




Net (Loss)/Profit Attributable to Equity Shareholders

USD: million



Sales & Marketing Expenses

USD: million




Sales & marketing expenses increased by 16.7% YOY

- ◆ Increase in marketing activities as Covid-19 pandemic came under control

Administrative Expenses

USD: million




Administrative expenses increased by 13.7% YOY

- ◆ Increase in staff cost

R&D Expenses

USD: million




R&D expenses increased by 60.8% YOY

- ◆ Due to increased investments in R&D projects

Net Cash Flow from Operating Activities

USD: million




Net operating cash flow decreased by \$114.8mn

- ◆ In line with the increase in loss from operations
- ◆ Payment of \$56mn income tax on the income recorded in 2020 from share transfer of surgical robot business

Net Cash Flow used in Investing Activities

USD: million




Net investing cash outflow increased by \$176.6mn

- ◆ Increased investment in JV and associates

Net Cash Flow from Financing Activities

USD: million



Net financing cash inflow increased by \$795.1mn

- ◆ Issuance of convertible bonds
- ◆ Cash inflow from the spin-off listing of heart valve business

Contents

- 1 Interim Result Highlights
- 2 Financial Review
- 3 Business Review
- 4 Outlook
- 5 Appendix – Financial Statements

Business Highlights




No.1

Player with **highest** domestic DES market share




World's Leading

Provider of cardiovascular intervention solutions



- DES Sales volume **more than doubled**, significantly increasing market share
 - Largest guaranteed purchase volume from GPO
 - Firebird2® & Firekingfisher® over-fulfilled GPO volume and contributed extra sales
- Balloon sales volume increased by **92.3%** YOY

Product Pipeline



Business by Sector

DES



Domestic

- 1H 2021 Revenue: \$42.0mn
- Sales volume surged **+124%** YOY
- Covering **2,700+** hospitals, newly penetrated **300+** hospitals



Overseas

- 1H 2021 Revenue: \$7.1mn, **+8.4%** YOY
- Europe sales **+251%** YOY, driven by channel expansion
- Robust sales growth **+134%** YOY in Middle East, Africa and Russia
- Resilient sales volume growth **+41%** YOY in India despite pandemic impact
- Firehawk® Liberty included in reimbursement list of **6** countries/regions; newly added **South Korea, Belarus and Turkey**
- 10** new registration approvals in **9** countries/regions



R&D

- Firehawk® proceeded TARGET IV NA trial in US and launched TARGET FIRST trial in EU
- Firesorb®'s FUTURE-II trial one-year results showed Firesorb® is comparable in **angiographic and clinical efficacy** to world's leading coronary drug-eluting stents


Balloon

- Domestic:** 1H 2021 revenue \$8.6mn, **88.5%** YOY
 - Penetrated **280+** hospitals with hospital coverage reaching **1,000+**
 - Sales volume increased by **114%** YOY
- Overseas:** 1H 2021 revenue \$0.9mn, **26.0%** YOY
 - 7** new registration approvals in **4** countries/regions, further expanding global footprint

Active Devices & Accessories

- Accessories sales volume increased by **over 100%** YOY, highly contributing to the profit
- Coronary Rotational Atherectomy Catheter & Microcatheter **completed type verification**

Non-China Business Highlights



Sales Highlights

- ◆ 1H 2021 revenue \$ 95.0mn, **+20.9%** YOY; net loss narrowed down by **68%** YOY
 - France sales +34% YOY thanks to effective management under direct sales model
 - Japan sales increased by 15% YOY despite all the COVID-19 driven impacts
- ◆ **Increasing customer conversions** generated from positive customer feedback, high-quality training program and sound cooperation with distributors
- ◆ Launched **Profemur® Gladiator®** HA Coated Collared Hip Stem & **Profemur® Gladiator®** Cemented Collared Hip Stem, expanding existing hip stem portfolio

R&D Progress

- ✓ **5 CE & 2 FDA approvals**
 - **CE:** Profemur® Cemented Femoral Stem, Procotyl® P Cup, Hip Head Tensioner
 - **CE & FDA:** Evolution® Kinematic Alignment instruments, Anterior PATH® instruments
- ◆ Initiated R&D project for Evolution® Tibia Bone Void Fillers
- ◆ Cooperated with various partners for development of surgical imaging and planning

Cost Savings

- ◆ Achieved over **\$5.0mn cost savings** with completion of 40+ cost improvement projects, including cross-border manufacturing collaboration and streamlining of operation teams
- ◆ Transferred partial manufacturing process to China to leverage global capabilities


Extensive Product Pipeline

Product	Pre-clinical	Clinical	Registration
Prime® Constrained Liner and Multi-hole Acetabular Cup System			Submitted for FDA application
DYNASTY® Dual Mobility Acetabular Hip System			Submitted for FDA application
Additive Manufactured Prime® Acetabular Cup			Submitted for FDA application
Evolution® Kinematic Alignment instrumentation			✓ Obtained FDA & CE certification
Anterior PATH® instrumentation			✓ Obtained FDA & CE certification
Profemur® Cemented XM® Femoral Stem			✓ Obtained CE certification
Procotyl® P Revision Acetabular Cup System			✓ Obtained CE certification
Hip Head Tensioner Device			✓ Obtained CE certification


China Business Highlights

USD: million

Revenue



Revenue Breakdown by Product Type



GPO

Evolution® Medial-Pivot Knee System and FemurElite-S Hip System entered **Group A** of GPO, expected to further increase market share



Business by Sector


Joints

- ◆ 1H 2021 revenue: \$12.3mn, +32.0% YOY
- ◆ Sales substantially increased; penetrated **400+** hospitals with total coverage of ~950 hospitals
- ◆ Made-in-China hip products, launched in 2020, realized substantial sales growth of **593.4% YOY**, covering **256** hospitals
- ◆ **Advance®** Medial-Pivot Knee System received “**15A**” **ODEP** (Orthopedic Data Evaluation Panel) – **1st Chinese company** to receive the **highest** ODEP rating
- ◆ **Cost reduced** for joint instrument by roughly **30% YOY** while **production capacity nearly tripled**

Spine & Trauma


- ◆ 1H 2021 revenue: \$2.5mn, +83.7% YOY
- ◆ Robust sales growth contributed by **sales channels expansion** and **new product launches** in 2020 (**Piscis® II** Injectable Artificial Bone Fusion Cage & **Takin® II** Hollow Spine Minimally Invasive System)

Comprehensive Made-in-China Product Pipeline



Non-China Business Highlights

Non-China Revenue



Sales Highlights


- ◆ 1H 2021 revenue: \$102.3mn, +17.3% YOY
- ◆ Global sales gradually recovered with profitability improved
- ◆ Realized robust sales growth of +87.3% in US, 45.8% in Japan and +16.1% in EMEA
- ◆ Launched **Alizea™/Borea™** pacemakers in Europe with large-scale commercial deployment

R&D Progress

- ✓ 6 CE approvals
 - **Alizea™/Borea™** Bluetooth® pacemakers
 - **SmartView Connect™** home monitor
 - **Ulys™/Edis™/Gali™** ICD & CRT-D
- ◆ **Invicta™** ICD lead launched clinical trial


MicroPort® CRM
Announced to raise
US\$150mn
Post-money valuation
of **US\$1,250mn**

Product Pipeline for Non-China Business



China Business Highlights

China Revenue



Sales Highlights


- ◆ 1H 2021 revenue: \$6.0mn, +95.0% YOY
- ◆ **Made-in-China pacemaker: revenue +116% YOY**
 - Demand recovery with increasing hospital visits
 - **Rapid market expansion:** newly penetrated 134 hospitals, covering 584 hospitals thanks to excellent brand recognition & cost-effectiveness

R&D Progress

- ◆ Submission of registration to **NMPA: Platinum™** ICDs, **Platinum™** CRT-Ds, and **BeFlex™** MRI lead
- ◆ **ENO™/TEO™/OTO™** pacemakers and **Vega™** lead completed 1st patient enrollment in **CAPRI** study
- ◆ **BonaFire™** passive pacing lead is under clinical trial

No.1
Domestic player with
Highest market share


Product Pipeline for China Business



Business Highlights

USD: million

Key Financials



Sales Highlights

- ◆ 1H 2021 revenue: \$55.8mn, +68.6% YOY
- ◆ Reewarm® PTX Drug Coated Balloon Catheter, launched in 2020, realized **significant sales growth** with no. of hospitals covered doubling to **250+**
- ◆ Castor®, the world's 1st thoracic branch stent-graft system, penetrating ~80 hospitals with total coverage of **~600** hospitals
- ◆ Minos® maintained a rapid sales growth, covering **250+** hospitals (adding ~90 hospitals)

Overseas Expansion


- ◆ Castor® Branched Aortic Stent Graft System completed 1st implantation in **Spain, Argentina and Italy**
- ◆ Minos® Abdominal Aortic Stent Graft System completed 1st implantation in **Brazil**, marking the System's **10th** overseas market
- ◆ Hercules® Low Profile Thoracic Stent Graft System completed 1st implantation in **Turkey**

Extensive Product Pipeline

	Product	Pre-clinical	Clinical	Registration
Aortics Stents	Talos® Thoracic Stent Graft System 		Submitted for NMPA review	
	Branched Aortics Stent Graft System		Design verification	
Peripheral Products	Drug Balloon Catheter		Design verification	
	High-pressure Balloon Catheter		Submitted for NMPA review	
	Iliac Venous Stent System		Under clinical trial	
	Vena Cava Filter		Upon clinical trial	
	Thrombectomy Catheter		Upon clinical trial	
Surgical	Fontus® Branched Surgical Stent Graft System 		Submitted for NMPA review	
Oncological	TIPS Stent Graft System		Completed animal study	

 Product admitted to the Green Path

Business Highlights



Sales Highlights

- ◆ 1H 2021 revenue: \$25.4mn, +114.5% YOY
- ◆ Apollo™ revenue +89.5% YOY, newly penetrating **105** hospitals with total coverage of **1,372** hospitals, remaining as **No.1 player** in Intracranial stenosis treatment
- ◆ Tubridge® revenue more than doubled with hospital coverage totaling **475** hospitals
- ◆ Strong sales growth drives from **new product launches**: NUMEN® Coil Embolization System, NUMEN FR® Coil Detachment System and U-track® Intracranial Support Catheter System


Overseas Expansion

- ◆ NUMEN® & NUMEN FR® **approved** by **CE**
- ◆ NUMEN® completed **1st overseas commercial implantation** in Chile in Aug 2021

Strategic Investment

- ◆ Led **\$50mn** equity investment in **Rapid Medical's** series D funding, becoming **Top 1 shareholder**
- ◆ As **exclusive distributor** of three flagship products in Greater China - Tigertriever® Adjustable Clot Retriever, Comaneci® Aneurysm Embolization Assist Device & Tigertriever® 13

Extensive Product Pipeline



Business Overview

Key Financials

USD: million



Gross Profit Margin



IPO

- Successful spin-off and separate listing on HKEx (4 Feb 2021)
- Net IPO proceeds: HKD 2,717.2mn (~\$360mn)



Business Highlights

1H 2021 revenue \$13.4mn, +121.8% YOY

GP margin expanded 110bps to 55.1% due to better cost control & scale economies

- Extensive nationwide coverage with fast-growing market share
 - Penetrated 76 hospitals in 1H 2021, with total coverage of 220 hospitals
 - Covered 19 out of Top 20 hospitals
 - No.1 market position in approx. 100 hospitals
- Subsidiary Chengdu Xintuo opened in May 2021, expected to secure key raw materials and further improve profitability
- VitaFlow® completed 1st overseas commercial implantation in Argentina in Aug 2021
- VitaFlow®'s 4-year follow-up study showed the rates of all-cause mortality and major stroke were 12.7% and 2.7%, respectively, further proving the safety and efficacy for long-term clinical use

Strategic Investment

- Follow-on investment of approximately \$2.5mn in Valcare, to accelerate R&D of its mitral and tricuspid product candidates, namely Amend™, Corona™ and Trivid™

Extensive Product Pipeline with Solid Progress

	Product	Pre-clinical	Clinical	Registration
TAVI	VitaFlow Liberty™ 	• Expected to be approved by NMPA		
	VitaFlow® III	• Design fixing		
	VitaFlow® Balloon Expandable	• Design stage		
Mitral Replacement	In-house Developed Replacement Product	• Under animal studies		
	AltaValve™ 	• Under early feasibility study		
	Corona™ 	• Under animal studies		
Mitral Repair	In-house Developed Edge to Edge	• Design fixing		
	Amend™ 	• Under clinical trial		
Tricuspid Repair	Trivid Repair Product	• Design stage		
	Edge to Edge Repair Product	• Design stage		
Surgical	Surgical Valve	• Design stage		
Procedural Accessories	Alwide® Plus Balloon Catheter 	✓ Obtained NMPA approval in Aug 2021		

 Product admitted to the Green Path

Business Overview

IPO Progress



- ◆ Application accepted for spin-off and separate listing on HKEx

Business Highlights



1 Approved Product



DFVision® 3D

- Expected to be **first Chinese-developed 3D electronic laparoscope** to commence commercial launch in China

2 Registration Stage



Toumai®

- **First & the only** Chinese-developed four-arm laparoscopic surgical robot having completed registrational clinical trial
- Demonstrated non-inferiority in primary efficacy endpoint of surgery success rate to da Vinci Si with good safety profile

Honghu

- **The only** Chinese-developed joint replacement surgical robot with self-developed robotic arm
- Completed registrational clinical trial in Jul 2021, with all primary and secondary efficacy endpoints met

Strategic Cooperation



- ◆ Established JVs with three industry leading surgical robot companies, **Robocath, NDR and Biobot**
- ◆ Cooperate in various areas, e.g. development, assembling and distribution of surgical robots in Greater China





Extensive Product Pipeline

	Product	Pre-clinical	Clinical	Registration
Laparo-scopic	Toumai® Laparoscopic Surgical Robot			Submitted for NMPA approval
	DFVision® 3D Electronic Laparoscope			✓ Obtained NMPA approval
Orthopedic	Honghu Orthopedic Surgical Robot			Submitted for NMPA approval ¹
	Spine Surgical Robot			Design stage
Natural Orifice	Trans-bronchial Surgical Robot			Design stage
	TAVR Surgical Robot			Design stage
Panvas-cular	R-One™ Vascula Interventional Surgical Robot			Design verification stage in China Obtained CE mark in 2019
	Automated Needle Targeting Robotics System ("ANT")			Design stage in China Obtained CE mark ² in 2020
Percu-taneous	iSR'obot™ Mona Lisa Robotic Transperine Prostate Biopsy System ("Mona Lisa")			Design verification stage in China Obtained CE & FDA approval in 2017

Contents

- 1 Interim Result Highlights
- 2 Financial Review
- 3 Business Review
- 4 Outlook
- 5 Appendix – Financial Statements

Innovative Product Pipeline Fueling Long-Term Growth

Cardio-vascular	Firehawk® Plus NMPA&CE 	Microcatheter NMPA	Coronary Stent Graft System NMPA 	Firefighter™ Pro/NC Pro NMPA 	Rapamycin Drug-coated Balloon NMPA&CE 	Coronary Rotational Atherectomy System NMPA&CE 	Firesorb® Bioresorbable Scaffolds NMPA&CE 	Intravascular Lithotripsy Balloon NMPA&CE 
Orthopedics	Prime® Constrained Liner & Multi-hole Acetabular Cup System FDA 	DYNASTY® Dual Mobility Acetabular Hip System FDA 	Profemur® Cemented XM® Femoral Stem CE 	SoSuperior™ + NMPA 	VenusOne Acetabular System NMPA 	Evolution Medial Pivot Knee® Localization NMPA 		
CRM	Alizea™ MRI Bluetooth® Pacemaker CE&FDA 	Rega™ MRI Pacemaker NMPA 	Ulys™/Edis™/Gali™ MRI ICD/CRT-D CE 	Invicta™ MRI ICD lead & Navigo™ MRI CRT lead CE 	ENO™ MRI Pacemaker family NMPA 	BonaFire™ MRI Conditional Passive Lead NMPA 	Leadless Pacemaker NMPA&CE 	
Endo-vascular	Fontus® Branched Surgical Stent Graft System NMPA 	Talos® Thoracic Stent Graft System NMPA 	High-pressure Balloon Catheter NMPA 	Iliac Venous Stent System NMPA 	Vena Cava Filter NMPA 	Thrombectomy Catheter NMPA 	Drug Balloon Catheter NMPA 	Branched Aortics Stent Graft System NMPA 
Neuro-vascular	Neurohawk™ Thrombectomy Device NMPA 	Tigertriever™ Revascularization Device NMPA 	Intracranial Distal Access Catheter NMPA 	Diveer™ Intracranial Balloon Catheter NMPA 	NUMEN® Silk 3-D Coil Embolization System NMPA 	Balloon Protection Guiding Catheter NMPA 	Tubridge® II Vascular Reconstruction Device NMPA 	
Heart Valve	VitaFlow® III (self-expanding) NMPA	VitaFlow® Balloon Expandable NMPA	Mitral Replacement: AltaValve™ Corona™ In-house Developed Product 	Mitral Repair: Amend™ In-house Developed Edge to Edge 	Tricuspid Repair: Trivid Repair Product Edge to Edge Repair Product 	Surgical Valve NMPA		
Surgical Robot	Toumai® Laparoscopic Surgical Robot NMPA 	Honghu Orthopedic Surgical Robot NMPA 	R-One™ Vascular Interventional Surgical Robot NMPA 	Spine Surgical Robot NMPA 	Trans-bronchial Surgical Robot NMPA 	TAVR Surgical Robot NMPA 	iSR'obot™ Mona Lisa Robotic Transperineal Prostate Biopsy System NMPA 	
Surgical Devices	VitaSprings™ Membrane Oxygenator NMPA 	Femoral Arterial & Venous Cannula NMPA	Arterial Micro-Embolic Filter (new type) NMPA	ECMO NMPA 				
Electro-physiology¹	Tissue Temperature Measuring Catheter NMPA	High Density Mapping Catheter NMPA	Cryoablation Catheter NMPA 	IceMagic® Cardiac Cryoablation System NMPA 	Contact Force-Sensing Catheter NMPA	Renal RF Ablation System NMPA		

Contents

- 1 Interim Result Highlights
- 2 Financial Review
- 3 Business Review
- 4 Outlook
- 5 Appendix – Financial Statements

USD'000	1H 2021	1H 2020	Var.
Revenue	384,611	306,922	25.3%
Cost of sales	(137,003)	(89,334)	53.4%
Gross profit	247,608	217,588	13.8%
Other net income	24,622	30,808	-20.1%
Research and development costs	(117,064)	(72,803)	60.8%
Distribution cost	(130,689)	(111,972)	16.7%
Administrative expenses	(102,987)	(90,614)	13.7%
Other operating costs	(5,466)	(9,611)	-43.1%
Loss from operations	(83,976)	(36,604)	129.4%
Finance cost	(21,905)	(16,071)	36.3%
Gain on deemed disposal of a subsidiary	8,219	-	N/A
Gain on deemed disposal of interest in equity-accounted investees	523	-	N/A
Share of losses of equity-accounted investees	(5,255)	(2,522)	108.4%
Loss before taxation	(102,394)	(55,197)	85.5%
Income tax	(12,282)	(13,565)	-9.5%
Loss for the period	(114,676)	(68,762)	66.8%
Attributable to: Equity shareholders of the Company	(90,266)	(65,562)	37.7%

Appendix II - Consolidated Balance Sheet

USD'000	30 June 2021	31 Dec 2020	Var.
Non-current assets			
Investment properties	16,669	5,284	215%
Other property, plant and equipment	483,620	481,203	1%
Intangible assets	143,403	138,397	4%
Prepayments for non-current assets	10,184	7,724	32%
Goodwill	157,423	159,483	-1%
Equity-accounted investees	321,656	87,063	269%
Other financial assets	26,627	19,605	36%
Deferred tax assets	14,109	15,502	-9%
Other non-current assets	101,630	75,009	35%
Total non-current assets	1,275,321	989,270	29%
Current assets			
Inventories	244,203	240,187	2%
Trade and other receivables	249,273	236,976	5%
Pledged deposits and time deposits	13,622	623	2087%
Cash and cash equivalents	1,699,410	1,002,077	70%
Derivative financial assets	1,480	-	N/A
Total current assets	2,207,988	1,479,863	49%
Current liabilities			
Trade and other payables	239,409	372,472	-36%
Contract liabilities	39,297	62,008	-37%
Lease liabilities	15,492	12,074	28%
Interest-bearing borrowings	58,436	10,891	437%
Income tax payable	4,091	52,682	-92%
Derivative financial liabilities	-	9,252	-100%
Total current liabilities	356,725	519,379	-31%
Net current assets	1,851,263	960,484	93%

USD'000	30 June 2021	31 Dec 2020	Var.
Non-current liabilities			
Interest-bearing borrowings	119,323	181,988	-34%
Lease liabilities	50,921	42,774	19%
Deferred income	33,383	37,844	-12%
Convertible bonds	720,492	48,583	1383%
Contract liabilities	29,486	29,855	-1%
Other payables	109,348	203,023	-46%
Deferred tax liabilities	4,111	4,122	0%
Derivative financial liabilities	7,124	13,619	-48%
Total non-current liabilities	1,074,188	561,808	91%
CAPITAL AND RESERVE			
Share capital	18	18	-
Reserves	1,472,443	1,127,945	31%
Total equity attributable to equity shareholders of the Company	1,472,461	1,127,963	31%
Non-controlling interests	579,935	259,983	123%
Total equity	2,052,396	1,387,946	48%

USD'000	1H 2021	1H 2020	Var.
Cash (used in)/generated from operations	(44,105)	19,581	-325%
Income tax paid	(69,425)	(14,308)	385%
Income tax refund received	7,168	3,176	126%
Net cash (used in)/generated from operating activities	(106,362)	8,449	-1359%
Net cash used in investing activities	(214,485)	(37,861)	467%
Net cash generated from financing activities	1,015,998	220,942	360%
Net increase in cash and cash equivalents	695,151	191,530	263%
Cash and cash equivalents at 1 January	1,002,077	280,077	258%
Effect of foreign exchange rate changes	2,182	(334)	-753%
Cash and cash equivalents at 30 June	1,699,410	471,273	261%